Dalrada Shares Very Encouraging Results from Second CerVIA Test Kit Study
Proactive Investor’s Christine Corrado meets with Dalrada’s Chief Medical Officer, Dr. Payal Keswarpu, to discuss the results of the second screening study of cerVIA test kit.
Dalrada Corporation (OTCQB:DFCO)?Chief Medical Officer Dr. Payal Keswarpu tells Proactive it has shown positive results of a second screening study of its patent-pending cerVIA kit used to test for cervical cancer on 100 women in India. The women, aged 31 to 65, were screened with Pap smear and visual inspection with acetic acid (VIA) using the firm's kit and the study revealed VIA's accuracy at 91%. Data from the first cervical cancer clinical study in India revealed that cerVIA had been 96.8% specific.
*Medical devices *Pathology *Prevent Cancer
2 年Please publish the results, if not already done.